Search
Kiniksa Pharmaceuticals International PLC
KNSAAdd to Watchlist
77.090USD
+0.780+1.02%
Close 10-06 16:00（ET）
6.01BMarket Cap
79.25P/E TTM
Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Kiniksa Pharmaceuticals International PLC in the past month.
Buy
3 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
96.714USD+27.61%
KNSA Analyst Recommendation Trends
In the current month, KNSA has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KNSA average Analyst price target in the last month is 96.714.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
3
3
3
3
3
3
5
5
5
5
5
5
5
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
8
7
KNSA Analyst Rating for Peer Comparison
Updated: Oct 6, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Eli Lilly and Co
LLY
10
18
3
1
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, KNSA EPS is projected to reach 0.371 in FY2026Q3, following reported EPS of 0.328 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.37
0.20
0.30
0.37
0.37
Actual
0.19
0.30
0.33
--
--
Surprise
-50.09%
+46.71%
+9.73%
--
--
FAQs
What is Kiniksa Pharmaceuticals International PLC's expected revenue for the next quarter?
Kiniksa Pharmaceuticals International PLC's expected revenue is 259.60M.
What is Kiniksa Pharmaceuticals International PLC's price target?
Analysts forecast that Kiniksa Pharmaceuticals International PLC's price target is USD 96.71, with the highest forecast at USD 108.00 and the lowest forecast at USD 87.00.
How have Kiniksa Pharmaceuticals International PLCKNSA's recent earnings per share performed?
The market expectation was USD 0.33, while Kiniksa Pharmaceuticals International PLCKNSA's earnings per share (EPS) for the previous quarter was USD 0.30. EPS for the next quarter is expected at USD 0.37.
What is the analyst rating for Kiniksa Pharmaceuticals International PLC?
Based on the ratings of Kiniksa Pharmaceuticals International PLC's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.